At the time of writing, Adaptimmune Therapeutics Plc ADR [ADAP] stock is trading at $0.06, up 2.93%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ADAP shares have gain 4.55% over the last week, with a monthly amount drifted -43.09%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Adaptimmune Therapeutics Plc ADR [NASDAQ: ADAP] stock has seen the most recent analyst activity on July 29, 2025, when H.C. Wainwright downgraded its rating to a Neutral. Previously, Mizuho downgraded its rating to Neutral on June 26, 2025, and kept the price target unchanged to $0.50. On July 30, 2024, H.C. Wainwright initiated with a Buy rating and assigned a price target of $4 on the stock. Scotiabank started tracking the stock assigning a Sector Outperform rating and suggested a price target of $3.15 on May 30, 2024. Bryan Garnier initiated its recommendation with a Buy and recommended $3.60 as its price target on March 24, 2023. Guggenheim upgraded its rating to Buy for this stock on January 03, 2023, but kept the price target unchanged to $5. In a note dated November 09, 2022, Mizuho upgraded an Buy rating on this stock but restated the target price of $9.
For the past year, the stock price of Adaptimmune Therapeutics Plc ADR fluctuated between $0.05 and $1.33. Currently, Wall Street analysts expect the stock to reach $2.83 within the next 12 months. Adaptimmune Therapeutics Plc ADR [NASDAQ: ADAP] shares were valued at $0.06 at the most recent close of the market. An investor can expect a potential return of 4616.67% based on the average ADAP price forecast.
Analyzing the ADAP fundamentals
According to Adaptimmune Therapeutics Plc ADR [NASDAQ:ADAP], the company’s sales were 65.66M for trailing twelve months, which represents an -89.22% plunge. Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -2.52%, Pretax Profit Margin comes in at -2.52%, and Net Profit Margin reading is -2.61%. To continue investigating profitability, this company’s Return on Assets is posted at -1.3, Equity is 41.03 and Total Capital is -2.08. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.69.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.0576 points at the first support level, and at 0.0555 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.0609, and for the 2nd resistance point, it is at 0.0621.
Ratios To Look Out For
It is important to note that Adaptimmune Therapeutics Plc ADR [NASDAQ:ADAP] has a current ratio of 1.52. In addition, the Quick Ratio stands at 1.29 and the Cash Ratio stands at 0.51. Considering the valuation of this stock, the price to sales ratio is 0.24.
Transactions by insiders
Recent insider trading involved Behbahani Ali, Director, that happened on Aug 18 ’25 when 14.67 million shares were sold. Director, Behbahani Ali completed a deal on Aug 15 ’25 to sell 4.83 million shares. Meanwhile, Affiliate New Enterprise Associates, 14 bought 13.83 million shares on Aug 15 ’25.
